Evidence map›Paper›PMID 28057656›Full record

ArticleBMJ open2017

EpideMiology and control measures of outBreaks due to Antibiotic-Resistant orGanisms in EurOpe (EMBARGO): a systematic review protocol.

Nithya Babu Rajendran, Beryl Primrose Gladstone, Jesús Rodríguez-Baño, Frangiscos Sifakis, Andreas Voss, Yehuda Carmeli, Francesco Robert Burkert, Panagiota Gkolia, Evelina Tacconelli

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Emergence and establishment of KPC-2-producing ST11 Klebsiella pneumoniae in a general hospital in Shanghai, China.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018
    Article
  5. Peptide Extract fromBioMed research international · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Nithya Babu RajendranDivision of Infectious Diseases, Department of Internal Medicine 1, DZIF Partner Centre, University Hospital Tuebingen, Tuebingen, Germany.
Beryl Primrose GladstoneDivision of Infectious Diseases, Department of Internal Medicine 1, DZIF Partner Centre, University Hospital Tuebingen, Tuebingen, Germany.
Jesús Rodríguez-BañoDepartment of Infectious Diseases and Clinical Microbiology, Hospital Universitario Virgen Macarena, Servicio Andaluz de Salud, Sevilla, Spain.
Frangiscos SifakisAstraZeneca, Gaithersburg, Maryland, USA.
Andreas VossDepartment of Clinical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
Yehuda CarmeliNational Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Francesco Robert BurkertDivision of Infectious Diseases, Department of Internal Medicine 1, DZIF Partner Centre, University Hospital Tuebingen, Tuebingen, Germany.
Panagiota GkoliaDivision of Infectious Diseases, Department of Internal Medicine 1, DZIF Partner Centre, University Hospital Tuebingen, Tuebingen, Germany.
Evelina TacconelliDivision of Infectious Diseases, Department of Internal Medicine 1, DZIF Partner Centre, University Hospital Tuebingen, Tuebingen, Germany.
Andalusian Health Service · ESAstraZeneca (United States) · USCanisius-Wilhelmina Ziekenhuis · NLTel Aviv Sourasky Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionImproving our understanding of outbreaks due to antibiotic-resistant bacteria (ARB) and their control is critical in the current public health scenario. The threat of outbreaks due to ARB requires multifaceted efforts. However, a global overview of epidemiological characteristics of outbreaks due to ARB and effective infection control measures is missing. In this paper, we describe the protocol of a systematic review aimed at mapping and characterising the epidemiological aspects of outbreaks due to ARB and infection control measures in European countries. METHODS AND ANALYSIS: The databases MEDLINE, Web of Knowledge and Cochrane library will be searched using a 3-step search strategy. Selection of articles for inclusion will be performed by 2 reviewers using predefined eligibility criteria. All study designs will be included if they report an outbreak and define the microbiological methods used for microorganism identification. The target bacteria will be methicillin-resistant and vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, ceftazidime-resistant and carbapenem-resistant Acinetobacter baumannii, ceftazidime-resistant and carbapenem-resistant Pseudomonas aeruginosa, ciprofloxacin-resistant Escherichia coli, extended-spectrum β-lactamase-producing E. coli and Klebsiella pneumoniae, carbapenem-resistant and carbapenamase-producing Enterobacteriaceae. Data will be extracted using a tailored pilot tested form and the quality of reporting will be assessed using the ORION (Outbreak Reports and Intervention Studies Of Nosocomial infections) tool. Data will be synthesised and reported by the type of ARB, setting and country. Infection control measures and bundles of measures will be described. The effectiveness will be reported as defined by the authors. Regression analysis will be used to define independent factors associated with outbreaks' control. Heterogeneity between studies will be assessed by forest plots and I² statistics. ETHICS AND DISSEMINATION: Ethical approval is not applicable for this study. Findings will be disseminated through journal publication and conference presentations and talks.

Indexed as

Drug Resistance, BacterialAcinetobacter baumanniiBacterial InfectionsBacterial Proteinsbeta-Lactamasesbeta-Lactam ResistanceCarbapenemsCeftazidimeCiprofloxacinDisease OutbreaksEnterobacteriaceaeEscherichia coliEuropeHumansKlebsiella pneumoniaeMethicillin-Resistant Staphylococcus aureusBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsCeftazidimeCiprofloxacinantimicrobial resistanceEPIDEMIOLOGYoutbreak

Identifiers

PMID28057656
PMCPMC5223682
OpenAlexW2568327818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.